Blood, transfusion, allogeneic

Reduction of allogenic blood transfusions in elective surgery Subcutaneous 300 units/kg/day 10 days before day of, and 4 days after, surgery. 

Spahn DR, Waschke KF, Standi T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery Results of a European phase 3 study. Anesthesiology 2002-, 97 1338-49. 

Anemia of chronic renal failure patients, zidovudine-treated HIV-infected patients and cancer patients on chemotherapy reduction of allogeneic blood transfusion in surgery patients... 

Additionally, there is increasingly strong evidence that allogeneic blood transfusion reduces the immune responsiveness (or immunocompetence) of the organism, thus predisposing a transfusion recipient to infectious complications and septicemia. Fewer infections were observed in patients receiving autologous... 

Blood transfusions also appear to increase the risks of recurrence and spread of certain cancers, and to reduce long-term survival following surgeryThis risk may again be lower when autologous rather than allogeneic blood is usedJ ... 

Heiss, M.M. Mempel, W. Delanoff, C. Jauch, K.-W. Gabka, C. Mempel, M. Dieterich, H.-J. Eissner, H.-J. Schildberg, F.-W. Blood transfusion-modulated tumor reccurence first results of a randomized study of autologous vs allogeneic blood transfusion in colorectal cancer surgery. J. Clin. Oncol. 1994, 12, 1859-1867. 

Successful allogeneic blood transfusion, one of the most important life-saving procedures of modern medicine, was first reported in Its use grew... 

In some countries there has been a marked increase in the use of autologous blood transfusion, since it is known that blood-borne viruses, such as HIV, can be transmitted by allogeneic blood transfusion (24). 

Qutaishat S. Autologous blood transfusion evaluation of an alternative strategy in reducing exposirre to allogeneic blood transfusion. Immunol Invest 1995 24(l-2) 435-41. 

GoodnoughLT, Shander A, Spence R. Bloodless medicine Chnical care without allogeneic blood transfusion. Transfusion 2003 43 668-676. 

Klaesson S, Ringden O, Ljungman P et al. (1994). Reduced blood transfusion requirements after allogeneic bone marrow transplantation results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant, 13, 397-402. 

Tuman, KJ., McCarthy. RJ.. O Connor. CJ.. McCarthy. W.E., and Ivankovich, A. (19%) Aspirin Does Not Increase Allogeneic Blood Transfusion in Reoperative Coronary Artery Surgery, Anesth. Analg. 83,1178-1IM. 

Vamvakas EC. White-blood-cell-contain-ing allogeneic blood transfusion and postoperative infection or mortality an updated meta-analysis. Vox Sang 2007 92(3) 224-32. 

Munoz M, Garcia-Erce JA, Cuenca J, Bisbe E, Naveira E. On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic... 

Verdln-Vasquez, R.C., Zepeda-Perez, C., Ferra-Ferrer, R., CMvez-Negrete, A., Contreras, R, and Barroso-Aranda, J. Use of Perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery Clinical trial. Artif Cells Blood Substit Immobil Biotechnol 34(4) 433-454,2006. 

G-CSF is widely used to mobilise bone marrow stem cells into the peripheral blood to support both autologous and allogeneic peripheral blood progenitor transplantation. The use of peripheral blood progenitors as opposed to bone marrow progenitors is associated with earlier neutrophil and platelet recovery, fewer red cell transfusions and earlier discharge from hospital. 

Hebert, P.C. Schweitzer, I. Calder, L. Blajchman, M. Giulivi, A. Review of the clinical practice literature on allogeneic red blood cell transfusion. Can. Med. Assoc. J. 1997,156 (Suppl 11), S9-S26. 

Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, Champlin RE, Korbling M. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim the M.D. Anderson Cancer Center experience. Transfusion 1999 39(6) 555-60. 

The standard UK definition of leucocyte-depletion is less than 5 x 106 residual leucocytes per unit of red cells or platelets (Pamphilon et al., 1999). Thus, if blood products are used, they should always be irradiated to 2 Gy prior to use, to ensure that the immunosuppressed recipient does not develop transfusion-mediated graft-versus-host disease because of the presence of residual viable lymphocytes in the donated blood product. Such graft-versus-host disease is usually fatal (Aoun et al., 2003 Schroeder, 2002), and causes overwhelming skin desquamation, diarrhoea and liver failure secondary to fibrosis of the biliary system. Even if immunosuppression is given, this is usually insufficient to overcome the problem once allogeneic lymphocytes have engrafted in the recipient. 

Transfusion-related acute lung injury (TRALI) is a chnical syndrome characterized by bilateral pulmonary edema in association with transfusions of blood products. It has been reported following the infusion of allogeneic hematopoietic stem cells during BMT (30,31). 

---